[Identification of a metabolic immune regulator in the host that protects against influenzal pneumonia]

Rev Mal Respir. 2021 Jun;38(6):567-571. doi: 10.1016/j.rmr.2021.05.003. Epub 2021 May 20.
[Article in French]

Abstract

The 'flu, caused mostly by influenza A and B viruses, represents a major public health issue. Despite vaccines and antiviral drugs, the therapeutic arsenal is still suboptimal. Recently, several studies have reported the antiviral and anti-inflammatory properties of several host metabolites. Now, we show that a metabolite (called here "C2") has a potent anti-influenza activity by blocking the viral replication and by limiting the downstream pro-inflammatory signalling. These results pave the way for the development of innovative metabolic therapy against influenzal pneumonia.

Keywords: Antiviral therapy; Immunometabolism; Immunométabolisme; Influenza; Thérapie anti-grippale; Virus.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / therapeutic use
  • Humans
  • Influenza Vaccines* / therapeutic use
  • Influenza, Human* / drug therapy
  • Influenza, Human* / prevention & control
  • Pneumonia* / drug therapy
  • Pneumonia* / prevention & control
  • Virus Replication

Substances

  • Antiviral Agents
  • Influenza Vaccines